![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 37, 26259-26265, September 10, 1999
From the Previous studies have shown that normal
intestinal epithelial cells (IECs) are able to selectively activate
CD8+ T cells with suppressor activity, inducing
proliferation associated with the activation of both the CD8-associated
kinase p56lck and the T cell receptor (TCR)-associated kinase
p59fyn. This process appears to relate in part to a 180-kDa IEC
surface glycoprotein, gp180, which binds to CD8 and activates
CD8-associated p56lck. However, purified gp180 alone is unable
to induce T cell proliferation and does not activate p59fyn.
Because the class Ib molecule CD1d is expressed by IECs and monoclonal
antibodies (mAbs) against CD1d inhibit IEC-induced proliferation of
CD8+ T cells, co-immunoprecipitation and enzyme-linked
immunosorbent assay studies were performed, which demonstrated an
association of gp180 and CD1d on the IEC surface. Interestingly, the
activation of p59fyn in IEC-T cell co-cultures was blocked by
the anti-CD1d mAb D5 but not by the anti-gp180 mAb B9. Conversely,
treatment of IECs with mAb B9 inhibited IEC-induced activation of
p56lck but not p59fyn. More directly, a human CD1d
cDNA (FO-1 D5) transfectant was able to activate p59fyn but
not p56lck. These data suggest that the CD1d-gp180 complex on
the surface of IECs can be recognized by the TCR-CD8 co-receptor,
resulting in the activation of CD8+ T cells.
The goal of the systemic immune system is to generate specific
responses against foreign pathogens that result in their elimination. In contrast, whereas antigen exposure in the gastrointestinal tract
appears to be magnified due to dietary and microbial antigen load, the
immune response is limited or suppressed. This state of
nonresponsiveness to orally administered antigens is referred to as
oral tolerance (1-12). Although there have been several mechanisms
invoked to explain the development of this state, many studies have
shown that the activation of suppressor T cells is crucial for the
existence of oral tolerance (5, 6). Unfortunately, the mechanisms
responsible for the activation of this subset of T cells have not been
completely defined.
Previous studies have demonstrated that intestinal epithelial cells can
act as antigen-presenting cells capable of stimulating primed T cells
(13-16). Interestingly, despite the constitutive expression of class
II MHC1 molecules on these
cells, the T cells proliferating in these co-cultures are
CD8+ (17, 18). The subset of CD8+ T cells that
proliferate when co-cultured with IECs are phenotypically similar to
suppressor T cells (CD8+CD28 It is known that IECs express the nonclassical restriction elements
CD1d in humans and CD1 and TL in mouse (21-24). CD1d transcripts are
only observed within intestinal crypt cells, whereas protein expression
appears to be localized predominantly in the intestinal villus (25). On
the IEC, CD1d is restricted to the apical and lateral surfaces, placing
it in a potential location for interaction with local T cells (24).
Previous studies have documented that cytolytic intraepithelial
lymphocytes can be restricted by these class Ib molecules (26) and that
the proliferation of T cells in IEC-T cell co-cultures can be inhibited
by mAbs to CD1d in a human system (27). This molecule may, therefore,
serve as a restriction element for IEC-T cell interactions. However, in contrast to the conventional restriction element class I MHC, CD1d
fails to bind CD8.2 Thus, in
order for a TCR-CD8 co-receptor complex to form in this system, another
surface molecule must exist.
Studies in our laboratory have reported on two monoclonal antibodies
generated against intestinal epithelial cells that were capable of
inhibiting the IEC-induced proliferation of CD8+ T cells
and activation of the CD8-associated kinase p56lck (20). Both
of these mAbs, B9 and L12, recognize a 180-kDa glycoprotein, termed
gp180, which is expressed on epithelial cells in various organs and,
comparable to CD1d (28), the dominant expression pattern is on surface
rather than crypt epithelium. The monoclonal antibody B9
recognizes gp180 expressed by gastrointestinal epithelium, cortical
thymic epithelium, and placental syncytiotrophoblasts, whereas L12
recognizes gp180 expressed only by the epithelium of the
gastrointestinal and respiratory tract. The 180-kDa intestinal epithelial cell surface glycoprotein is a novel molecule capable of binding to CD82 and activating the CD8-associated
protein tyrosine kinase p56lck, but not the TCR-associated
kinase p59fyn (29). This is in contrast to studies using intact
intestinal epithelial cells, in which activation of p59fyn is
also seen. These data suggest that gp180 may be associated with a
molecule that is capable of interacting with the T cell receptor and
activating TCR-associated p59fyn.
Given the findings reported above, CD1d might be an eligible candidate
to aid gp180 in the activation and proliferation of CD8+ T
cells, including those with suppressor activity. In the present study,
we demonstrate that gp180 associates with CD1d and that this gp180-CD1d
complex is involved in the activation of CD8+ T cells.
Cell Isolation, Cell Lines, and Culture Conditions--
FO-1
cells transfected with human CD1d cDNA (FO-1 D5) have been
previously described (30). These transfected cells were maintained in
RPMI medium supplemented with 10% fetal calf serum, 20 mM
HEPES, 1% nonessential amino acids, 1% L-glutamine, 1%
penicillin/streptomycin, and 3 mg/ml G418 (Sigma). Untransfected FO-1
cells were cultured in similar media without G418 and served as a
negative control.
Peripheral blood mononuclear cells were isolated from leukocyte
concentrate packs and separated into T and non-T cells using rosetting
and density gradient centrifugation as described previously (27).
Briefly, heparinized venous blood was collected from normal donors and
separated by Ficoll-Paque (Amersham Pharmacia Biotech) density gradient
centrifugation. T cells and non-T cells were isolated from PBMCs by a
rosetting method using neuraminidase-treated sheep red blood cells
followed by Ficoll-Paque density gradient centrifugation.
Enterocytes were isolated by a method described previously (17, 27).
Surgical specimens were obtained from the operating room. Specimens
were washed extensively with PBS containing 1% penicillin/streptomycin
and 1% fungizone (Flow Laboratory Inc., McLean, VA). The mucosa was
stripped from the submucosa, cut into small pieces, and placed in 1 mM dithiothreitol (Sigma) for 5 min at room temperature to
remove the mucus. The pieces were then washed in PBS and incubated in
dispase (3 mg/ml in RPMI 1640 medium, Roche Molecular Biochemicals) for
30 min in a 37 °C shaking incubator. This was repeated four times.
The tissue pieces were removed and the cell suspension collected,
pooled, and centrifuged on a Percoll density gradient (Amersham
Pharmacia Biotech). Enterocytes located at the 0-30% interface were
washed three times with PBS and resuspended in RPMI medium with 0.1%
bovine serum albumin for co-culture experiments. Preparations of
purified enterocytes were >90% viable, and free of macrophages and B
cell contamination as determined by staining with anti-CD14 and
anti-CD20 mAbs (Coulter Corp., Hialeah, FL), and contaminated with only
2-4% intraepithelial lymphocytes (CD3+ cells).
Antibodies--
B9 is a murine IgG1 anti-human IEC monoclonal
antibody that appears to recognize a carbohydrate epitope on the novel
intestinal epithelial cell surface molecule gp180. Ascites was
generated at a concentration of 1 mg/ml and used at a 1:1000 dilution
for Western blotting, whereas 10 µg was used for immunoprecipitation studies. An irrelevant murine IgG1 antibody was used as a negative control whenever necessary.
Four monoclonal antibodies were used to detect CD1d. 3C11 and 1H1 are
rat IgM anti-mouse CD1 monoclonal antibodies, which have been
previously shown to cross-react with human CD1d (21, 22, 30).
Supernatants were harvested from the 1H1 or 3C11 hybridomas, and
antibody concentrations were adjusted to 10 µg/ml. D5 is a murine
anti-human CD1d monoclonal antibody generated against glutathione
S-transferase fusion protein of CD1d (31) and was a kind
gift of Dr. Steven Balk (Beth Israel Medical Center, Boston, MA). The
D5 antibody was used at a concentration of 5 µg/ml. 51.1.3 is a mouse
anti-human CD1d mAb raised against an Fc-fusion protein of CD1d (32)
and was the kind gift of Dr. Steve Porcelli (Brigham and Women's
Hospital, Boston, MA).
OKT3, OKT8, and W6/32 are hybridomas obtained from the American Type
Culture Collection (ATCC, Manassas, VA) that produce monoclonal
antibodies against CD3, CD8, and a nonpolymorphic domain of class I
MHC, respectively.
Isolation of Purified gp180--
2 × 107
intestinal epithelial cells were washed, resuspended in 1 ml of RPMI
medium with 1 unit of phosphoinositol phospholipase C (Sigma) and
incubated for 45 min at 37 °C. gp180 has previously been shown to
exist in two forms: a GPI-anchored, apically sorted form and a
transmembrane basolateral form (29). The cell suspension was
centrifuged for 10 min at 500 × g, and the cells and
supernatant were analyzed for released gp180 (GPI-anchored form)
through cell staining and Western blot.
Construction of CD1d-GST Fusion Proteins--
The CD1d-GST
fusion protein was constructed using the Co-culture, Immunoprecipitation, and Kinase Assays--
T cells
and intestinal epithelial cells were resuspended to achieve a
concentration of 1 × 107 cells/ml in 0.1% bovine
serum albumin-RPMI 1640 medium (w/v). Cells were prewarmed in a
37 °C water bath. For each reaction, one million T cells were placed
in a 1.5-ml Eppendorf tube and centrifuged for 5 s. The
supernatant was removed, and the pellet was loosened. One million
intestinal epithelial, FO-1 D5, or untransfected FO-1 cells were mixed
with the T cells, spun quickly for 20 s, and placed in a 37 °C
water bath. After 1, 2, or 5 min, 1 ml of ice-cold stop buffer (PBS
with 10 mM sodium orthovanadate) (Sigma) was added. The
pellet was resuspended in 100 µl of lysis buffer (20% PBS, 80%
dH2O, 100 mM Na2VO3, 1 mM PMSF, 5 mM iodoacetamide, 20 µg/ml
leupeptin, and 20 µg/ml aprotinin) (Sigma) and vortexed 20 times at
the start and end of a 30-min incubation on ice. As a positive control,
one million T cells were incubated with 10 µg/ml anti-CD8 antibody
(OKT8) for 30 min at 4 °C and cross-linked with 10 µg/ml rabbit
anti-mouse IgG antibody for 2 min at 37 °C. Time zero tubes were
prepared by adding stop buffer to individual tubes containing T cells
and either epithelial, FO-1 D5, or untransfected cells. The lysate from
these two tubes were then combined into one tube to account for all
constitutive kinases and substrates in both cell types. In some
experiments, the lysates from these co-culture conditions were
immunoprecipitated with a rabbit anti-human p59fyn or rabbit
anti-human p56lck antibody, which was covalently bound to
Sepharose beads (Santa Cruz Biotechnology, Santa Cruz, CA). These
conjugated antibodies were rotated with co-culture lysates (precleared
with rabbit serum-coated Sepharose 4B beads) for 1 h at 4 °C.
The beads were washed four times with PBS, and 75 µl of reducing
buffer (50 mM Tris-Cl, pH 6.8, 5% 2-ME, 10% glycerol, 1%
SDS) was added prior to boiling for 5 min. The resulting samples were
then run on a 10% SDS-PAGE gel and transferred to nitrocellulose paper
(Schleicher & Schuell Inc., Keene, NH). A mAb 4G10 anti-phosphotyrosine
(Upstate Biotechnology Inc., Lake Placid, NY) Western blot was then performed.
In other experiments, lysates of intestinal epithelial cells were
immunoprecipitated with murine anti-gp180 mAb B9, IgG1 (isotype control), or the anti-class I mAb W6/32 (negative control) to determine
whether an association between CD1d and gp180 existed. Protein
A-Sepharose beads were coated with 10 µg/ml rabbit IgG anti-mouse
immunoglobulin followed by primary antibody (isotype control,
anti-gp180, or anti-class I MHC). Each of these steps was performed for
1 h at room temperature while rotating. The beads were then washed
thoroughly with wash buffer (2 M Tris, pH 7.4, 0.5 M EDTA, 4 M NaCl), and the epithelial cell
lysate was rotated with the coated beads overnight at 4 °C. The
beads were washed five times with RIP buffer (10 mM Tris,
pH 8.0, 1.0 mM EDTA, 0.5% Nonidet P-40, 0.1 M
NaCl, 1 mg/ml ovalbumin, and 0.02% sodium azide) and resolved on
SDS-PAGE. After transferring to nitrocellulose, an anti-CD1d (D5) mAb
followed by an anti-gp180 (B9) mAb Western blot was performed.
When kinase assays were performed, beads were resuspended in 30 µl of
kinase buffer (10 mM MnCl2, 50 mM
Tris, pH 7.4) and mixed with 10 µCi of [ Western Blots--
A 10% SDS-PAGE gel was prepared, and one
million cell equivalents of protein was loaded per lane. The protein
was transferred from the gel to nitrocellulose paper and blocked with
5% milk for 1 h at room temperature. The membrane was then
incubated with 1 µg/ml of primary antibody (4G10, B9, D5, or isotype
control) overnight at 4 °C. The membrane was washed with PBS several
times and incubated in 1 µg/ml of HRP-conjugated goat anti-mouse Ig (Cappel, Durham, NC) antibody for 1 h at room temperature. The membrane was washed thoroughly with wash buffer (PBS, 0.05% Tween-20) prior to development using enzyme-linked chemiluminescence (NEN Life
Science Products) reagent.
Enzyme-linked Immunosorbant Assays--
gp180 was purified using
a B9 affinity column and diluted in coating buffer (dH20,
0.015 M Na2CO3, 0.03 M
NaHCO3, 3 mM NaN3). An optimal
dilution of gp180 (4 × 105 cell equivalents) was used
to coat 96-well Nunc ELISA plates at 4 °C, overnight. The plates
were washed five times with 100 µl/well of ELISA buffer (PBS, 0.05%
Tween-20) and blocked with 1% bovine serum albumin-PBS for 1 h at
room temperature. After washing, 1 µg/ml CD1d-GST fusion protein or
GST alone was added to the plates and incubated at room temperature for
1 h. The plates were then washed five times. Binding was detected
by incubating the plates with 5 µg/ml mouse anti-GST antibody for
1 h followed by 1 h of incubation with 10 µg/ml
HRP-conjugated goat anti-mouse Ig secondary antibody. After 100 µl of
HRP substrate (dH2O, 0.2 M NaPO4,
0.2 M Na2PO4, 0.001%
H2O2, 2 mM phenol, 1.2 mM 4-aminoantipyrine) was added, the plate was read by a
Genetic Systems microplate ELISA reader at 490 nm.
Flow Cytometry Cell Staining--
Intestinal epithelial cells
were isolated as described, and 1 × 105 cells per
condition were stained in a V-bottom 96-well plate. The cells were
washed three times with 0.1% bovine serum albumin in PBS. The
intestinal epithelial cells were incubated with 10 µg/ml isotype
control mAb (murine IgG1 or murine IgG2b), 10 µg/ml mouse IgG1
anti-gp180 (B9), or 10 µg/ml mouse IgG2b anti-CD1d (D5) monoclonal
antibody for 30 min at 4 °C. Cells were washed several times and
incubated with 10 µg/ml fluorescein isothiocyanate-conjugated goat
anti-mouse Ig (BIOSOURCE, Camarillo, CA) for an
additional 30 min at 4 °C. Cells were washed and resuspended in 400 µl of PBS. The percentage of positive cells and mean fluorescence
were analyzed by an Epics Profile III flow cytometer.
CD1d Associates with gp180 on the Surface of Intestinal Epithelial
Cells--
Our previous studies have shown that co-culturing IECs with
PBTs results in the activation of the TCR-associated p59fyn and
CD8-associated p56lck tyrosine kinases. Purified gp180 was
found to be responsible for the activation of the protein tyrosine
kinase p56lck but not p59fyn (29). It was, therefore,
hypothesized that another molecule might associate with gp180 and
interact with the TCR. Because anti-CD1d antibodies have been shown to
inhibit IEC-induced proliferation of CD8+ T cells, CD1d was
an eligible candidate to aid gp180 in the activation of
CD8+ T cells. Thus, the hypothesis that gp180 associates
with CD1d was studied.
Initial studies were performed to confirm that normal IECs express both
gp180 and CD1d on their surface. 1 × 105 cells per
condition were stained with B9, D5, and appropriate isotype controls to
confirm cell surface expression of gp180 and CD1d, respectively. The
cells were analyzed by an Epics Profile III flow cytometer. Fig.
1A illustrates that freshly
isolated intestinal epithelial cells do express both of these
molecules. A co-immunoprecipitation study was then performed using
these same freshly isolated intestinal epithelial cells (data not
shown) or HT29 cells. An intestinal epithelial cell lysate was prepared by lysing 1 × 107 intestinal epithelial cells in
lysis buffer containing 1% digitonin. The lysate was
immunoprecipitated with a murine IgG2b mAb isotype control or mAb D5.
An anti-gp180 (B9) followed by an anti-CD1d (D5) Western blot was then
performed. Fig. 1B documents the association of gp180 (180 kDa) and CD1d (37 kDa). The D5 mAb immunoprecipitated a 180-kDa band
consistent with gp180 (Fig. 1B, left panel, right lane), as well as a doublet at 37-kDa (right panel,
right lane), consistent with the form of CD1d isolated from
intestinal epithelial cells (24, 30). Similar results were observed
when 3C11 and 1H1 monoclonal antibodies were used (data not shown).
Although this figure provides data with intestinal epithelial cells
lysed in a digitonin based lysis buffer, there appeared to be no
difference in intestinal epithelial cells lysed with either Nonidet
P-40 or Brij 97 (data not shown). Thus, the interaction between gp180 and CD1d appeared to be quite strong. In addition, it appears that
neither gp180 nor CD1d co-precipitated with the conventional restriction element class I MHC (data not shown).
In order to confirm these findings more directly, an enzyme-linked
immunosorbant assay was performed. An optimal concentration (4 × 105 cell equivalents) of gp180 was used to coat ELISA
plates, and 1 µg/ml CD1d-GST or control proteins were added to the
wells. A mouse anti-GST antibody (5 µg/ml) was then added followed by a HRP-conjugated goat anti-mouse IgG antibody to detect binding. As
seen in Fig. 2, the CD1d-GST fusion
protein bound gp180 to a significantly greater extent in comparison to
the control GST protein. Thus, by two experimental approaches, CD1d
appeared to be capable of associating with gp180.
CD1d Alone Does Not Activate the CD8-associated Protein Tyrosine
Kinase p56lck but Does Appear to Activate the TCR-associated
Kinase p59fyn--
Initial experiments conducted in our
laboratory suggested that CD1d was not involved in the activation of
CD8-associated p56lck in IEC-T cell co-cultures. This was
determined by mAb inhibition studies in which neither the 3C11 mAb nor
1H1 mAb inhibited IEC activation of p56lck. However, in order
to confirm that CD1d was not involved in the activation of
p56lck more directly, FO-1 cells stably transfected with human
CD1d cDNA (FO-1 D5) were co-cultured with peripheral blood T cells for varying incubation periods (0, 2, and 5 min). The reactions were
stopped with cold lysis buffer. The T cell lysates were
immunoprecipitated with mouse IgG anti-human p56lck antibody,
the proteins were resolved by SDS-PAGE, and an anti-phosphotyrosine Western blot was performed. In this experiment (Fig.
3A), no phosphorylation of the
CD8-associated protein tyrosine kinase p56lck was seen. As a
control, untransfected FO-1 cells were cultured with peripheral blood T
cells and subjected to the same conditions as the FO-1 D5 cells. In
order to document that the CD1d expressed by the transfectant was
functional, we utilized the same cell lysates to determine whether CD1d
could activate the TCR-associated kinase p59fyn. FO-1 D5 cells
were co-cultured with peripheral blood T cells for varying incubation
periods (0, 2, and 5 min) in the presence or absence of the mouse IgG
anti-human CD1d mAb, D5. As a control, untransfected FO-1 cells were
cultured with peripheral blood T cells and subjected to the same
conditions as the FO-1 D5 cells. All reactions were stopped with cold
lysis buffer. The T cell lysates were immunoprecipitated with rabbit
anti-human p59fyn antibody, and an anti-phosphotyrosine Western
blot was performed. As seen in Fig. 3B, phosphorylation of
p59fyn was readily seen with FO-1 D5-T cell co-cultures, which
was blocked by the monoclonal antibody D5. FO-1 cells do not express
either CD1d or gp180, thus explaining the inability of this cell line to activate p56lck or p59fyn. In addition, the ability
of FO-1 D5 cells to activate p59fyn indicates that CD1d is
functional (31). The identification of Lck in these lysates serves as a
control for equal loading of protein, given the absence of bands in
Fig. 3A.
Antibodies against CD1d Do Not Inhibit CD8-associated Kinase
p56lck but Do Inhibit the TCR-associated Kinase p59fyn
in Freshly Isolated Intestinal Epithelial Cell-T cell
Co-cultures--
We have previously shown that co-culturing purified
gp180 with CD8+ T cells results in the activation of
CD8-associated p56lck. The studies represented in Fig. 3 appear
to indicate that CD1d may be responsible for the activation of the
TCR-associated kinase p59fyn but not of the CD8-associated
kinase p56lck. Because the use of a CD1d transfectant may not
actually reflect in vivo events, we set out to confirm this
in our isolated IEC-T cell co-culture system.
An antibody to CD1d (D5) was incubated with IECs prior to being
co-cultured with T cells. Excess antibody was removed by washing three
times with RPMI 1640. After varying incubation periods at 37 °C, the
T cells were lysed, immunoprecipitated with rabbit anti-human
p56lck, resolved on SDS-PAGE, and subjected to an
anti-phosphotyrosine Western blot. As seen in Fig.
4A, the D5 monoclonal antibody
was incapable of inhibiting the activation of p56lck. To
determine the impact that this same antibody has on the activation of
the TCR-associated p59fyn kinase, the same T cell lysates from
IEC-T cell co-cultures treated with D5 were immunoprecipitated with the
rabbit anti-human p59fyn antibody covalently bound to Sepharose
beads (Santa Cruz). As can be seen in Fig. 4B, the anti-CD1d
monoclonal antibody D5 was capable of inhibiting the activation of the
TCR-associated protein tyrosine kinase p59fyn in this
co-culture system. These results suggested that CD1d was capable of
interacting with the TCR and activating the TCR-associated p59fyn kinase but was incapable, directly or indirectly, of
activating p56lck. It therefore appeared that CD1d was capable
of interacting with the T cell receptor and activating p59fyn
in both in vitro (CD1d transfectants) and ex vivo
(freshly isolated intestinal epithelial cells) systems. Because the
anti-CD1d mAb D5 appeared to inhibit the ability of intestinal
epithelial cells to phosphorylate p59fyn in T cells, we next
asked whether this observation could be confirmed using another
anti-CD1d monoclonal antibody, 51.1.3. Intestinal epithelial cells were
incubated with either 51.1.3 or D5 mAb (10 µg/ml) for 30 min on ice
and then washed thoroughly. The intestinal epithelial cells were
co-cultured with PBTs for 0, 2, or 5 min at 37 °C. The T cells were
lysed and immunoprecipitated with a rabbit anti-p59fyn
antibody, and the protein was resolved by SDS-PAGE, transferred to
nitrocellulose paper, and subjected to an anti-phosphotyrosine Western
blot. As seen in Fig. 5, the relative
intensities of the bands resolved at 59 kDa indicated that whereas the
D5 mAb almost completely inhibited the ability of intestinal epithelial
cells to activate the TCR-associated p59fyn kinase, the
anti-CD1d mAb 51.1.3 inhibited p59fyn activation by 50%
compared with the isotype control. These results further support the
notion that CD1d on intestinal epithelial cells was capable of
activating the phosphorylation of p59fyn in CD8+ T
cells.
gp180 Is Able to Bind Extracellularly to CD1d--
Experiments
conducted to this point indicated that CD1d associates with gp180 on
the surface of intestinal epithelial cells and that this complex is
involved in the activation of CD8+ T cells. We wanted to
then determine whether gp180 was capable of binding extracellularly to
CD1d or whether membrane anchoring was required. Peripheral blood T
cells were cultured with either FO-1 cells (control transfection cells)
or FO-1 D5 cells (FO-1 cells transfected with human CD1d cDNA), in
the presence or absence of purified gp180, or all three for 0 or 2 min
at 37 °C. To test the ability of soluble gp180 to bind CD1d,
purified gp180 was incubated with FO-1 or FO-1 D5 cells and left
unwashed or washed thoroughly, prior to being co-cultured with PBTs.
The T cells were lysed and immunoprecipitated with an
anti-p56lck antibody. The protein was then resolved by SDS-PAGE
and subjected to an anti-phosphotyrosine Western blot. As seen in Fig.
6, the relative intensities of the bands
resolved at 56 kDa indicated that soluble gp180 was capable of binding
to membrane-bound CD1d in both washed and unwashed conditions. These
results further support the notion that gp180 is capable of associating
with CD1d.
Although the role of classical restriction elements has been
relatively clearly defined, the function of the structurally related
class Ib proteins has not yet been thoroughly investigated. Recent
studies from several groups suggest that class Ib molecules may be
involved in stress responses or in T cell responses against nonprotein
antigens (34, 35). These molecules include the CD1 family of proteins.
The CD1 family of nonclassical class I-like proteins are encoded
outside the MHC, and most members have limited homology to classical
MHC class I restriction elements (21, 22, 30, 34, 36). CD1d is a
nonpolymorphic isoform of the CD1 family that is prominently expressed
by intestinal epithelial cells. The mouse CD1d homologue has been shown
to be capable of binding peptides generally larger that those bound by
classical restriction elements (36); however, the recent x-ray
crystallographic structure of CD1d (37) suggests that it more likely
binds lipids or glycolipids, similar to CD1b and CD1c. In addition,
CD1d may be endosomally localized, like CD1b (38), and hence peptide and/or lipid (37) association with CD1d could conceivably occur within
classical class II loading compartments (exogenous antigen pathway) or
on the cell surface. The immunoregulatory function of CD1d has not been
clearly defined, but its presence on the surface of intestinal
epithelial cells lends support to the notion that it may serve as a
regulator of mucosal immune responses to antigens of undefined origin
(39). Indeed, previous studies have shown that intraepithelial
lymphocyte killing of intestinal epithelial cell lines can be
CD1d-restricted, and PBT cell proliferation induced by intestinal
epithelial cells is inhibited by anti-CD1d antibodies (26, 27).
Mucosal surfaces, such as those found in the gastrointestinal tract,
are continuously exposed to antigen; however, immune responses are not
mounted to most dietary and microbial antigens. This state of systemic
nonresponsiveness, which can also be induced by feeding antigen to a
host (oral tolerance), is a unique feature of the mucosal immune
system. Although the mechanisms involved in the induction of mucosal
tolerance may be multifold, several groups have reported that
CD8+ T cells play a role in transferring tolerance to naive
animals. Previous studies have demonstrated that antigen presentation
by intestinal epithelial cells results in the activation of
CD8+CD28 The activation of these CD8+ T cells by intestinal
epithelial cells appears to involve the CD8 molecule. Monoclonal
antibodies against CD8 but not CD4 inhibit IEC-induced proliferation of
T cells in response to IECs. Interestingly, antibodies recognizing conventional restriction elements do not inhibit IEC-induced activation and proliferation of CD8+ T cells (20). Therefore, other
molecular interactions were analyzed.
Two monoclonal antibodies, B9 and L12, identify a novel 180-kDa
intestinal epithelial cell glycoprotein, gp180, which is capable of
interacting with the CD8 molecule. We have shown that gp180 binds to
CD8 molecules2 and activates the CD8 Data generated in this study clearly indicate that gp180 does not act
alone in the activation and proliferation of CD8+ T cells
in response to IECs. Because it has been previously determined that
anti-CD1d antibodies inhibit the proliferation of CD8+ T
cells by intestinal epithelial cells (27), we examined the role that
CD1d plays in the activation of these T cells. It was clearly
demonstrated that CD1d associates with the glycoprotein gp180 in the
absence of The key question relates to the nature of the antigen presented by the
nonpolymorphic molecule, CD1d, in our allogeneic co-culture system.
Several possibilities exist. First, alloreactive T cells may recognize
processed class I or class II fragments in the antigen binding cleft of
CD1d. Alternatively, proteins found in serum (both human serum and
fetal calf serum used in cell culture) may be taken up by the
nonpolymorphic restriction element, CD1d, expressed on IECs and
presented to T cells. Thus, CD1d on cell lines and freshly isolated
intestinal epithelial cells could be constantly loaded with peptides
(or lipids/glycolipids) derived from serum. Finally, it may be that
CD1d has limited polymorphisms not previously appreciated. Zeng
et al. (37) suggested that CD1 is incapable of binding
peptide due to its deep hydrophobic pocket; however, Castano
et al. (36), using a peptide display library, showed that
CD1 was capable of associating with peptides larger that those bound by
classical class II molecules. The response to CD1d-presented peptide
(or nonpeptide) may be limited, but it is present. The other issue
relates to the cell population activated. Clearly, there are
CD1d-restricted double negative T cells in the peripheral blood and
presumably within the mucosa. The subpopulations of CD8+ T
cells expanded in our co-culture system may exist as
"presuppressor" cells. If such regulatory cells arise from a
distinct subpopulation, it could well explain the difficulty in clearly
identifying suppressor T cells in the past.
In our postulated model, gp180 associates with the nonclassical class I
molecule CD1d on the surface of intestinal epithelial cells. More
specifically, we postulate that each component of this complex has a
unique function: gp180 binds to the CD8 molecule, resulting in the
activation of the CD8-associated kinase p56lck, whereas CD1d
interacts with the TCR, causing the phosphorylation of the
TCR-associated kinase p59fyn. The gp180-CD1d complex thus
appears more like classical class I, capable of interacting with the
TCR-CD8 co-receptor complex. This postulated model may account for
several features observed in the gastrointestinal tract. The existence
of this complex could explain the presentation of exogenous antigen to
CD8+ T cells by IECs (if CD1d exists in an endosomal
compartment, as does CD1b), the presence of predominantly
CD8+ T cells in the IEC compartment, and the poor
activation of mucosal lymphocytes by conventional antigen-presenting
cells. The necessity for the activation of suppressor T cells in the
gut is clear. Any inability to do so is costly, resulting in
inflammation and the loss of functional integrity in the
gastrointestinal tract. The use of distinct molecules and restriction
elements provides further evidence for the differences between systemic
and mucosal immunity. This dichotomy may evolve from the differences in
antigen load and the requirement for controlled rather than active
immune responses in the gastrointestinal tract.
*
This work was supported by United States Public Health
Service Grants AI 24671, AI 41583, and AI 23504 (to L. M.); DK44319, DK51362, and AI53056 and the Crohn's and Colitis Foundation (to R. S. B.); and AI09682 (to H. S. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
This work was completed in partial fulfillment of a Ph.D. thesis.
To whom correspondence should be addressed: Dept. of Immunology, Genentech, Inc., One DNA Way, South San Francisco, CA 94080.
Tel.: 650-225-6829 Fax: 650-225-8221; E-mail:
nicola@gene.com.
2
N. A. Campbell and L. Mayer, unpublished data.
The abbreviations used are:
MHC, major
histocompatibility complex;
IEC, intestinal epithelial cell;
mAb, monoclonal antibody;
PBT, peripheral blood T cell;
ELISA, enzyme-linked
immunosorbent assay;
HRP, horseradish peroxidase;
GST, glutathione
S-transferase;
PBS, phosphate-buffered saline;
TCR, T cell
receptor;
PAGE, polyacrylamide gel electrophoresis;
GAM, goat
anti-mouse Ig;
RAM, rabbit anti-mouse IgG.
The Nonclassical Class I Molecule CD1d Associates with the Novel
CD8 Ligand gp180 on Intestinal Epithelial Cells*
§,
Division of Clinical Immunology, Mount Sinai
Medical Center, New York, New York 10029 and the ¶ Division of
Gastroenterology, Brigham and Women's Hospital,
Boston, Massachusetts 02115
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
) (19). These T
cells inhibit primary, secondary, and unrelated mixed lymphocyte
reactions, as well as B cell responses in vitro in an
antigen-nonspecific manner. The addition of anti-CD8 monoclonal antibodies to these co-cultures have supported the contention that the
CD8 molecule itself is important in the activation of CD8+
T cells by intestinal epithelial cells (IECs) with the activation of
the CD8-associated protein tyrosine kinase p56lck being a
necessary but not sufficient event (20). Interestingly, the addition of
monoclonal antibodies against classical restriction elements, class I
and class II MHC, do not inhibit the activation of these
CD8+ T cells, thus suggesting some novel form of interaction.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1-
3 domains of CD1d in a
pGEX vector (Amersham Pharmacia Biotech) (33). For large scale
preparations of CD1d-GST fusion protein, 10 ml of transformed bacteria
grown freshly overnight was inoculated into 500 ml of LB medium with
ampicillin selection. This was incubated for 90 min at 37 °C. After
adding 0.1 mM
isopropyl-1-thio-
-D-galactopyranoside, the bacterial
culture was grown for an additional 4 h. The culture was spun in a
Sorvall centrifuge for 10 min at 3000 × g at room temperature and resuspended in 6 ml of STE buffer (10 mM
Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA). It was
then spun for 10 min at 1500 × g. The pellet was
resuspended in 24 ml of 100 µg/ml lysozyme in STE along with protease
inhibitors (0.1 mg/ml PMSF and 20 µg/ml aprotinin) and incubated on
ice for 15 min prior to adding 5 mM dithiothreitol and
1.5% sarkosyl in STE. Bacterial cell walls were broken using a tissue
homogenizer for 15 min, and pellets were obtained by spinning in a
Sorvall SS-34 rotor at 23,500 × g for 30 min. After
adding 4% Triton X-100 (v/v), 2.5 ml of glutathione agarose beads
(Sigma) were incubated with the lysate for 2 h at 4 °C on an
orbital rocker. The beads were spun down, transferred to
microcentrifuge tubes, and washed 6-8 times with 1 ml of cold PBS
containing 0.5% Triton X-100 (v/v). The final wash was with PBS alone,
and CD1d-GST protein was eluted by rocking at 4 °C for 10 min in
0.75 ml of elution buffer (75 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM dithiothreitol, 0.1% Triton
X-100 (v/v)) containing 100 mM reduced glutathione. The
supernatant (eluant) was saved, and another 200 µl of elution buffer
was added to elute the remaining fusion protein. When the eluate was
resolved by SDS-PAGE and stained with Coomassie, a single band at 65 kDa was seen, the approximate mass of the CD1d-GST fusion protein.
-32P]ATP
(Amersham Pharmacia Biotech) for 30 min at room temperature. The enzyme
reaction was stopped by adding 15 µl of 4× reducing buffer (as
described previously) and boiling for 5 min.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (26K):
[in a new window]
Fig. 1.
A, freshly isolated intestinal
epithelial cells express surface gp180 and CD1d. Freshly isolated
intestinal epithelial cells (1 × 105 cells per
condition) were stained with an isotype control (mouse IgG1 or IgG2b),
mouse IgG1 anti-human gp180 (B9), or mouse IgG2b anti-human CD1d (D5)
monoclonal antibodies. Fluorescein isothiocyanate-conjugated goat
anti-mouse Ig antibody was used as the secondary detection antibody.
Yellow line (A), control well cells were stained
with 10 µg/ml IgG1 or IgG2b isotype control. Black line
(B), cells were stained with 10 µg/ml D5 mAb. Red
line (C), cells were stained with 10 µg/ml B9 mAb.
Panel A indicates that the intestinal epithelial cells used
for panel B express both gp180 and CD1d on their cell
surface. B, gp180 co-immunoprecipitates with the class Ib
molecule, CD1d. An HT29 intestinal epithelial cell lysate
(1 × 107 cell equivalents) was immunoprecipitated
with either mouse IgG2b mAb (control) or mouse IgG2b anti-CD1d (D5) and
the immunoprecipitated proteins resolved on a 10% SDS-PAGE gel. An
anti-gp180 (left panel) followed by an anti-CD1d
(right panel) Western blot was then performed. Left
panel: lane 1, HT29 lysate was immunoprecipitated with mouse IgG2b
monoclonal antibody; lane 2, HT29 lysate immunoprecipitated
with mouse IgG2b anti-human CD1d (D5) antibody. Right panel: lane
1, HT29 lysate immunoprecipitated with mouse IgG2b monoclonal
antibody; lane 2, HT29 lysate immunoprecipitated with mouse
IgG2b anti-human CD1d (D5) antibody. This figure shows that gp180
appears to associate with CD1d, which is represented by a 37-kDa
doublet.

View larger version (15K):
[in a new window]
Fig. 2.
gp180 binds to a CD1d-GST fusion
protein. The wells of Nunc ELISA plates were coated with purified
gp180 or left uncoated. Lane 1, GST, anti-GST, and GAM-HRP
in the absence of coating of the plate with gp180. Lane 2, control, in which no gp180 was coating the plate, and CD1d-GST,
anti-GST, and GAM-HRP were added. In lanes 3-5, an optimal
concentration (4 × 105 cell equivalents) of gp180 was
used to coat the wells. Lane 3, the GAM-HRP lane indicates
that GAM-HRP does not bind to gp180 directly (gp180 + GAM-HRP).
Lane 4, the GST fusion protein was added to the gp180-coated
wells, followed by an anti-GST mAb and GAM-HRP. Lane 5, the
CD1d-GST fusion was added to the gp180-coated wells, followed by an
anti-GST mAb and GAM-HRP. A dramatic difference can be seen between the
wells containing CD1d-GST alone and those with gp180 plus
CD1d-GST.

View larger version (19K):
[in a new window]
Fig. 3.
A, CD1d does not activate
CD8-associated protein tyrosine kinase p56lck.
Either the cell line transfected with CD1d cDNA, FO-1 D5, or the
untransfected control FO-1 was cultured with peripheral blood T cells
for 0, 2, or 5 min. The cells were then lysed and were
immunoprecipitated with an anti-p56lck antibody (Santa Cruz),
and an anti-phosphotyrosine Western blot was performed. Lane
1, negative control of T cells alone. Lane 2, control
of T cells stimulated with anti-CD3 (OKT3) mAb and cross-linked with
RAM for 2 min. Lane 3, positive control of T cells
stimulated with anti-CD8 (OKT8) mAb and cross-linked with RAM for 2 min. Lanes 4-6, FO-1 cells co-cultured with PBTs for 0, 2, and 5 min. Lanes 7-9, FO-1 cells treated with anti-CD1d mAb
D5 for 30 min prior to being co-cultured with PBTs for 0, 2, and 5 min.
Lanes 10-12, FO-1 D5 cells co-cultured with PBTs for 0, 2, and 5 min. Lanes 13-15, FO-1 D5 cells treated with
anti-CD1d mAb D5 for 30 min prior to being co-cultured with PBTs for 0, 2, and 5 min. Inset, the identification of Lck protein in
these lysates serves as a control for equal loading of protein given
the absence of bands. Compared with the positive control, in which T
cells were incubated with anti-CD8 antibodies, CD1d alone does not
appear to activate the CD8-associated protein tyrosine kinase
p56lck. This experiment was repeated three times. B,
CD1d appears to activate the TCR-associated protein tyrosine kinase
p59fyn. Lysates from FO-1 D5 or FO-1-PBT co-cultures (treated
or untreated with the anti-CD1d D5 mAb), as described in a,
were immunoprecipitated with an anti-p59fyn antibody (Santa
Cruz), and an anti-phosphotyrosine Western blot was performed.
Lane 1, negative control of T cells alone. Lane
2, control of T cells stimulated with anti-CD8 mAb and
cross-linked with RAM for 2 min. Lane 3, positive control of
T cells stimulated with anti-CD3 mAb and cross-linked with RAM for 2 min. Lanes 4-6, FO-1 co-cultured with PBTs for 0, 2, and 5 min in the presence of an irrelevant isotype control mAb. Lanes
7-9, FO-1 cells preincubated with anti-human CD1d antibody (D5)
for 30 min on ice prior to being co-cultured with PBTs for 0, 2, and 5 min. Lanes 10-12, FO-1 D5 cells co-cultured with PBTs for
0, 2, and 5 min in the presence of an irrelevant isotype control mAb.
Lanes 13-15, FO-1 D5 cells preincubated with anti-human
CD1d antibody (D5) for 30 min prior to being co-cultured with PBTs for
0, 2, and 5 min. Inset, the identification of Fyn protein in
these lysates serves as a control for equal loading of protein. Only
the CD1d cDNA transfected cell line was capable of activating
TCR-associated p59fyn, and this was blocked by the addition of
the anti-CD1d mAb D5. This figure is representative of four
experiments.

View larger version (19K):
[in a new window]
Fig. 4.
A, anti-CD1d antibodies do not appear to
be capable of inhibiting IEC-induced activation of p56lck.
Lysates from IEC-PBT co-cultures (treated with the anti-CD1d D5 mAb or
untreated) were immunoprecipitated with anti-p56lck antibody
(Santa Cruz), and an anti-phosphotyrosine Western blot was performed.
Lane 1, negative control of T cells alone. Lane
2, negative control of T cells stimulated with anti-CD3 mAb and
cross-linked with RAM for 2 min. Lane 3, positive control of
T cells stimulated with anti-CD8 mAb and cross-linked with RAM for 2 min. Lanes 4-7, IECs co-cultured with PBTs in the presence
of the isotype control for 0, 1, 2, and 5 min. Lanes 8-11,
IECs preincubated with anti-CD1d antibody (D5) and then co-cultured
with PBTs for 0, 1, 2, or 5 min. This figure is representative of two
experiments. B, antibodies against CD1d appear to inhibit
the activation of TCR-associated protein tyrosine kinase
p59fyn. Lysates from IEC-PBT co-cultures (treated or untreated
with the anti-CD1d D5 mAb) were immunoprecipitated with
anti-p59fyn antibody, and an anti-phosphotyrosine Western blot
was performed. Lane 1, negative control of T cells alone.
Lane 2, negative control of T cells stimulated with anti-CD8
mAb and cross-linked with RAM for 2 min. Lane 3, positive
control of T cells stimulated with anti-CD3 mAb and cross-linked with
RAM for 1 min. Lane 4, positive control of T cells
stimulated with anti-CD3 mAb and cross-linked with RAM for 2 min.
Lanes 5-8, IECs preincubated with an irrelevant isotype
control were co-cultured with PBTs for 0, 1, 2, or 5 min. Lanes
9-12, IECs preincubated with anti-CD1d antibody (D5) and then
co-cultured with PBTs for 0, 1, 2, or 5 min. This figure is
representative of four experiments.

View larger version (14K):
[in a new window]
Fig. 5.
Anti-CD1d antibody 51.1.3 partially inhibits
the ability of intestinal epithelial cells to activate TCR-associated
p59fyn kinase in CD8+ suppressor T cells.
Lysates from intestinal epithelial cell-T cell co-cultures treated with
isotype control, anti-CD1d D5 mAb, or anti-CD1d 51.1.3 mAb were
immunoprecipitated with an anti-p59fyn antibody, resolved by
SDS-PAGE, and subjected to an anti-phosphotyrosine Western blot.
Lane 1, negative control of T cells alone. Lane
2, positive control of T cells stimulated with anti-CD3 monoclonal
antibody and cross-linked with RAM for 2 min. Lane 3, negative control of T cells stimulated with anti-CD8 mAb and
cross-linked with RAM for 2 min. Lanes 4-6, IECs
preincubated with an irrelevant isotype control were co-cultured with
PBTs for 0, 2, and 5 min. Lanes 7-9, IECs preincubated with
anti-CD1d antibody (D5) and then co-cultured with PBTs for 0, 2, and 5 min. Lanes 10-12, IECs preincubated with anti-CD1d antibody
(51.1.3) and co-cultured with PBTs for 0, 2, and 5 min. The relative
intensity depicted represents the percent of density of phosphorylated
p59fyn under antibody-treated conditions compared with the
isotype control lanes.

View larger version (12K):
[in a new window]
Fig. 6.
gp180 is able to bind extracellularly to
CD1d. Lysates from peripheral blood T cells treated with FO-1
cells (control transfection cells), FO-1 D5 cells (FO-1 cells
transfected with human CD1d cDNA), purified gp180, or gp180-pulsed
FO-1 or FO-1 D5 cells were immunoprecipitated with an
anti-p56lck antibody, resolved by SDS-PAGE, and subjected to an
anti-phosphotyrosine Western blot. Lane 1, negative control
of T cells alone. Lane 2, negative control of T cells
stimulated with anti-CD3 monoclonal antibody and cross-linked with RAM
for 2 min. Lane 3, positive control of T cells stimulated
with anti-CD8 mAb and cross-linked with RAM for 2 min. Lanes
4 and 5, PBTs cultured with untransfected FO-1 cell for
0 or 2 min. Lanes 6 and 7, PBTs were co-cultured
with human CD1d cDNA transfected cells (FO-1 D5) for 0 or 2 min.
Lanes 8 and 9, PBTs cultured with purified gp180
for 0 or 2 min. Lane 10, FO-1 D5 cells were
preincubated with purified gp180 prior to being co-cultured with PBTs
for 2 min. Lane 11, FO-1 D5 cells were preincubated with
purified gp180 and washed four times prior to being co-cultured with
PBTs for 2 min. Lane 12, FO-1 cells were preincubated with
purified gp180 prior to being co-cultured with PBTs for 2 min.
Lane 13, FO-1 cells were preincubated with purified gp180
and washed four times prior to being co-cultured with PBTs for 2 min.
This figure is representative of two separate experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
T cells, which appear to have
suppressor activity (17). This suggests that the intestinal epithelial
cell may play a role in the activation of a subset of T cells, which
may be involved in the suppression of local immunity and, potentially,
systemic immune responses as well.
chain associated
protein tyrosine kinase p56lck (29). When the anti-gp180
monoclonal antibody B9 is added to IEC-T cell co-cultures, no
intestinal epithelial cell induced activation or proliferation of
CD8+ T cells is observed. This supports the fact that gp180
is critical to the activation of these CD8+ T cells.
2-microglobulin (31). More specifically, it
was shown that CD1d is not responsible for the activation of the
CD8-associated kinase p56lck but is responsible for the
activation of the TCR-associated kinase p59fyn. This is
consistent with previous studies that failed to show binding of CD1d to
CD8 molecules.2
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Wells, H. G.
(1911)
J. Infect. Dis.
9,
147-171
2.
Challacombe, S. J.,
and Tomasi, T. B.
(1980)
J. Exp. Med.
152,
1459-1472 3.
Thomas, H. C.,
and Parrot, M. V.
(1974)
Immunology.
27,
631-639[Medline]
[Order article via Infotrieve]
4.
Miller, S. D.,
and Hanson, D. G.
(1979)
J. Immunol.
123,
2344-2350 5.
Mattingly, J. A.,
and Waksman, B. H.
(1978)
J. Immunol.
121,
1878-1883 6.
Mattingly, J. A.,
Eardley, D. D.,
Kemp, J. D.,
and Gershon, R. K.
(1979)
J. Immunol.
122,
787-790 7.
Nagler-Anderson, C.,
Bober, L. A.,
Robinson, M. E.,
Siskind, G. W.,
and Thorbecke, G. J.
(1986)
Proc. Natl. Acad. Sci.
83,
7443-7446 8.
Khoury, S. J.,
Hancock, W. W.,
and Weiner, H. L.
(1992)
J. Exp. Med.
176,
1355-1364 9.
Santos, L. M.,
al-Sabbagh, A.,
Londono, A.,
and Weiner, H. L.
(1994)
Cell Immunol.
157,
439-447[CrossRef][Medline]
[Order article via Infotrieve]
10.
Miller, A.,
al-Sabbagh, A.,
Santos, L. M.,
Das, M. P.,
and Weiner, H. L.
(1993)
J. Immunol.
151,
7307-7315[Abstract]
11.
Mowat, A. M.
(1985)
Immunol.
56,
253-260[Medline]
[Order article via Infotrieve]
12.
Mowat, A. M.
(1987)
Immunol. Today
8,
93-98[CrossRef]
13.
Bland, P.
(1988)
Immunol. Today
9,
174-178[CrossRef][Medline]
[Order article via Infotrieve]
14.
Mayer, L.,
Eisenhardt, D.,
Salomon, P.,
Bauer, W.,
Plous, R.,
and Piccininni, L.
(1990)
Gastroenterology.
100,
3-12[Medline]
[Order article via Infotrieve]
15.
Bland, P. W.,
and Warren, L. G.
(1986)
Immunol.
58,
1-7[Medline]
[Order article via Infotrieve]
16.
Bland, P. W.,
and Whiting, C. V.
(1989)
Immunol.
68,
497-502[Medline]
[Order article via Infotrieve]
17.
Mayer, L.,
and Shlien, R.
(1987)
J. Exp. Med.
166,
1471-1483 18.
Bland, P. W.,
and Warren, L. G.
(1986)
Immunol.
58,
9-14[Medline]
[Order article via Infotrieve]
19.
Lui, Z.,
Tugulea, S.,
Cortesini, R.,
and Suciu-Foca, N.
(1998)
Int. Immunol.
10,
775-783 20.
Li, Y.,
Yio, X. Y.,
and Mayer, L.
(1995)
J. Exp. Med.
182,
1079-1088 21.
Bleicher, P. A.,
Balk, S. P.,
Hagen, S. J.,
Blumberg, R. S.,
Flotte, T. J.,
and Terhorst, C.
(1990)
Science
250,
679-682 22.
Blumberg, R. S.,
Terhorst, C.,
Bleicher, P.,
McDermott, F. V.,
Allan, C. H.,
Landau, S. B.,
Trier, J. S.,
and Balk, S. P.
(1991)
J. Immunol.
147,
2518-2524 23.
Hershberg, R.,
Eghtesady, P.,
Sydora, B.,
Brorson, K.,
Cheroutre, H.,
Modlin, R.,
and Kronenberg, M.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
9727-9731 24.
Somnay-Wadgaonkar, K.,
Musrat, A.,
Kim, H. S.,
Canchis, W. P.,
Balk, S. P.,
Colgan, S. P.,
and Blumberg, R. S.
(1999)
Int. Immunol.
11,
383-392 25.
Kasai, K.,
Matsuura, A.,
Kikuchi, K.,
Hashimoto, Y.,
and Ichimiya, S.
(1997)
Clin. Exp. Immunol.
109,
317-322[CrossRef][Medline]
[Order article via Infotrieve]
26.
Balk, S. P.,
Ebert, E.,
Blumethal, R. L.,
McDermott, F. V.,
Wucherpfennig, K. W.,
Landau, S. B.,
and Blumber, R. S.
(1991)
Science
253,
1411-1415 27.
Panja, A.,
Blumber, R. S.,
Balk, S. P.,
and Mayer, L.
(1993)
J. Exp. Med.
178,
1115-1120 28.
Canchis, P. W.,
Bhan, A. K.,
Landau, S. B.,
Yang, L.,
Balk, S. P.,
and Blumberg, R. S.
(1993)
Immunol.
80,
561-565[Medline]
[Order article via Infotrieve]
29.
Yio, X. Y.,
and Mayer, L.
(1997)
J. Biol. Chem.
272,
12786-12792 30.
Balk, S. P.,
Burke, S.,
Polischuk, J. E.,
Franz, M. E.,
Yang, L.,
Porcelli, S.,
Colgan, S. P.,
and Blumberg, R. S.
(1994)
Science
265,
259-262 31.
Kim, H. S.,
Garcia, J.,
Exley, M.,
Johnson, K. W.,
Balk, S. P.,
and Blumberg, R. S.
(1999)
J. Biol. Chem.
274,
9289-9295 32.
Exley, M.,
Garcia, J.,
Balk, S. P.,
and Porcelli, S.
(1997)
J. Exp. Med.
186,
109-120 33.
Colgan, S. P.,
Morales, V. M.,
Madara, J. L.,
Polischuk, J. E.,
Balk, S. P.,
and Blumberg, R. S.
(1996)
Am. J. Physiol.
271,
C276-C283 34.
Beckman, E. M.,
Porcelli, S. A.,
Morita, C. T.,
Behar, S. M.,
Furlong, S. T.,
and Brenner, M. B.
(1994)
Nature
372,
691-694[CrossRef][Medline]
[Order article via Infotrieve]
35.
Jullien, D.,
Stenger, S.,
Ernst, W. A.,
and Modlin, R. L.
(1997)
J. Clin. Invest.
99,
2071-2074[Medline]
[Order article via Infotrieve]
36.
Castano, A. R.,
Tangri, S.,
Miller, J. E. W.,
Holcombe, H. R.,
Jackson, M. R.,
Huse, W. D.,
Kronenberg, M.,
and Peterson, P. A.
(1995)
Science
269,
223-226 37.
Zeng, Z.-H.,
Castano, A. R.,
Segelke, B. W.,
Stura, E. A.,
Anderson, P. A.,
and Wilson, I. A.
(1997)
Science
277,
339-345 38.
Moody, D. B.,
Reinhold, B. B.,
Guy, M. R.,
Beckman, E. M.,
Frederique, D. E.,
Furlong, S. T.,
Ye, S.,
Reinhold, V. N.,
Sieling, P. A.,
Modlin, R. L.,
Besra, G. S.,
and Porcelli, S. A.
(1997)
Science
278,
283-286 39.
Blumberg, R. S.,
Colgan, S. P.,
and Balk, S. P.
(1997)
Clin. Exp. Immunol.
109,
223-225[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
I. Dotan, M. Allez, A. Nakazawa, J. Brimnes, M. Schulder-Katz, and L. Mayer Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-{gamma} Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1630 - G1640. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Attinger, L. Devine, Y. Wang-Zhu, D. Martin, J.-h. Wang, E. L. Reinherz, M. Kronenberg, H. Cheroutre, and P. Kavathas Molecular Basis for the High Affinity Interaction between the Thymic Leukemia Antigen and the CD8{alpha}{alpha} Molecule J. Immunol., March 15, 2005; 174(6): 3501 - 3507. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Oei, T. Kalb, P. Beuria, M. Allez, A. Nakazawa, M. Azuma, M. Timony, Z. Stuart, H. Chen, and K. Sperber Accessory cell function of airway epithelial cells Am J Physiol Lung Cell Mol Physiol, August 1, 2004; 287(2): L318 - L331. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Nohara, M. Kulka, R. E. Dery, F. L. Wills, N. S. Hirji, M. Gilchrist, and A. D. Befus Regulation of CD8 Expression in Mast Cells by Exogenous or Endogenous Nitric Oxide J. Immunol., November 15, 2001; 167(10): 5935 - 5939. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||